STEPHEN DAVIS - 15 Oct 2021 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
15 Oct 2021
Net transactions value
-$51,586
Form type
4
Filing time
19 Oct 2021, 17:30:22 UTC
Previous filing
07 Jul 2021
Next filing
23 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +5,938 +12% 55,869 15 Oct 2021 Direct F1, F2
transaction ACAD Common Stock Sale $51,586 -2,963 -5.3% $17.41 52,906 18 Oct 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -5,938 -50% $0.000000 5,938 15 Oct 2021 Common Stock 5,938 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 619 shares of the Issuer's common stock acquired by the reporting person on May 14, 2021 pursuant to an employee stock purchase program.
F3 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4 The restricted stock units vest in four equal annual installments beginning 10/15/19.